SCHEMBL6732732

SCHEMBL6732732

c1ccc(-c2ccccc2Oc2cccc(NCc3cccnc3)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.57
ALDH1A1 P00352 3/20 0.50
HTT P42858 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
PDE4B Q07343 1/20 0.49
CYP1A2 P05177 9/20 0.48
CYP3A4 P08684 9/20 0.48
CYP2C19 P33261 9/20 0.48
CYP2D6 P10635 8/20 0.48
CYP2C9 P11712 5/20 0.48
EPHX1 P07099 1/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 1/20 0.47
PABPC1 P11940 1/20 0.47
HSD17B10 Q99714 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6731979 0.83 LTA4H (0.56) LTA4HALDH1A1HTTHPGDSMN1; SMN2
SCHEMBL6732917 0.83 LTA4H (0.56) LTA4HALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL6733124 0.83 MAPT (0.59) LTA4HALDH1A1HTTHPGDSMN1; SMN2
SCHEMBL6727909 0.79 MAPK1 (0.70) LTA4HALDH1A1KDM4ERAB9AKMT2A
SCHEMBL19312422 0.77 LTA4H (0.60) LTA4HALDH1A1RAB9APDE4BCYP1A2
SCHEMBL14324148 0.77 ALDH1A1 (0.57) ALDH1A1HTTKDM4ENPC1RAB9A
SCHEMBL3214639 0.76 SMN1; SMN2 (0.49) LTA4HALDH1A1HTTHPGDSMN1; SMN2
SCHEMBL15583798 0.75 NAMPT (0.76) ALDH1A1HTTSMN1; SMN2KDM4ECYP2C9
SCHEMBL30642394 0.75 LTA4H (1.00) LTA4HALDH1A1RAB9ACYP1A2CYP3A4
SCHEMBL523753 0.75 LTA4H (1.00) LTA4HALDH1A1RAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 LTA4H 1721/4885ALDH1A1 1187/4885HTT 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.